CLLS

3.66

2.40% -0.09

アフターアワーズ： 3.66

Cellectis Adr (CLLS)

概要ニュース株価時系列オプションチェーンディスカッション予測

前日終値:

$3.75

開ける：

$3.91

24時間の取引高:

72,403

Relative Volume:

1.10

時価総額：

$368.16M

収益：

$5.15M

当期純損益:

$-65.35M

株価収益率:

-2.7111

EPS:

-1.35

ネットキャッシュフロー:

$-20.85M

1週間パフォーマンス:

-8.96%

1か月パフォーマンス:

+4.57%

6か月パフォーマンス:

+36.57%

1年パフォーマンス:

+185.94%

1日の値動き範囲:

$3.58

$3.911

1週間の範囲:

$3.58

$4.03

52週間の値動き範囲:

$1.10

$5.4796

Cellectis Adr Stock (CLLS) Company Profile

名前

Cellectis Adr

セクター

Healthcare (1108)

産業

Biotechnology (618)

電話

住所

職員

222

Twitter

@cellectis

次回の収益日

2024-11-04

最新のSEC提出書

CLLS's Discussions on Twitter

Compare CLLS vs VRTX, REGN, ARGX, ALNY, ONC

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
CLLS Cellectis Adr	3.66	377.22M	5.15M	-65.35M	-20.85M	-1.35
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Cellectis Adr Stock (CLLS) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2026-02-17	再開されました	Jefferies	Buy
2023-03-17	開始されました	Bryan Garnier	Buy
2022-05-18	アップグレード	Robert W. Baird	Neutral → Outperform
2022-01-06	ダウングレード	Wells Fargo	Overweight → Equal Weight
2021-11-30	開始されました	JMP Securities	Mkt Outperform
2021-11-08	ダウングレード	William Blair	Outperform → Mkt Perform
2021-10-08	ダウングレード	Robert W. Baird	Outperform → Neutral
2021-04-28	ダウングレード	Guggenheim	Buy → Neutral
2021-03-16	アップグレード	Robert W. Baird	Neutral → Outperform
2020-08-19	アップグレード	Citigroup	Neutral → Buy
2020-05-12	開始されました	Robert W. Baird	Outperform
2020-03-06	ダウングレード	Goldman	Neutral → Sell
2019-10-30	再開されました	Guggenheim	Buy
2019-08-09	開始されました	BTIG Research	Buy
2019-05-24	再開されました	Citigroup	Neutral
2019-03-14	開始されました	William Blair	Outperform
2018-12-19	開始されました	Goldman	Neutral
2018-07-16	開始されました	Barclays	Overweight
2018-03-16	開始されました	Guggenheim	Neutral
2017-09-05	ダウングレード	SunTrust	Buy → Hold
2017-09-05	繰り返されました	Wells Fargo	Outperform
2017-03-02	開始されました	Instinet	Buy
2017-02-28	開始されました	Wells Fargo	Outperform
2016-04-05	開始されました	Ladenburg Thalmann	Buy
2016-03-02	開始されました	Sun Trust Rbsn Humphrey	Buy
2015-07-20	開始されました	BofA/Merrill	Buy
2015-04-20	開始されました	Jefferies	Buy
2015-04-20	開始されました	Piper Jaffray	Overweight

すべてを表示

Cellectis Adr (CLLS) 最新ニュース

Feb 26, 2026

ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView — Track All Markets

Dec 29, 2025

Dec 22, 2025

Clear Street initiates Cellectis stock with Buy rating on CAR-T potential - Investing.com

Dec 22, 2025

Dec 21, 2025

Working capital per share of Cellectis S.A. Sponsored ADR – NASDAQ:CLLS - TradingView — Track All Markets

Dec 21, 2025

Dec 19, 2025

European ADRs Inch Up As 3D Printer Materialise Leads Gains - Finimize

Dec 19, 2025

Dec 16, 2025

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga

Dec 16, 2025

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm

Dec 16, 2025

Dec 15, 2025

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Sahm

Dec 15, 2025

Arbitration ruling partially terminates Cellectis-Servier license agreement - Investing.com

Dec 15, 2025

Nov 25, 2025

European ADRs Stay Put As Novo Nordisk Slides - Finimize

Nov 25, 2025

Nov 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm

Nov 24, 2025

Nov 21, 2025

Moligo and Cellectis show promise in non-viral gene editing method - Investing.com India

Nov 21, 2025

Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications - Sahm

Nov 21, 2025

Nov 19, 2025

Cellectis reports breakthrough in non-viral gene editing technique - Investing.com

Nov 19, 2025

Nov 18, 2025

Citizens maintains Cellectis stock rating with $8 target ahead of ASH update - Investing.com

Nov 18, 2025

Nov 14, 2025

European ADRs Slip As Gains And Losses Balance Out - Finimize

Nov 14, 2025

Nov 03, 2025

Cellectis to Present a Development Update for eti-cel at ASH 2025 - Chartmill

Nov 03, 2025

Oct 22, 2025

European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize

Oct 22, 2025

Oct 20, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Oct 20, 2025

Oct 18, 2025

Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail

Oct 18, 2025

Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines

Oct 18, 2025

Oct 17, 2025

Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com

Oct 17, 2025

Oct 16, 2025

Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga

Oct 16, 2025

Oct 14, 2025

Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView

Oct 14, 2025

Oct 13, 2025

Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews

Oct 13, 2025

Cellectis Adr (CLLS) 財務データ

収益

当期純利益

現金流量

EPS

RPRX

$45.68

3.69%

MRNA

$53.83

6.87%

ROIV

$29.72

0.68%

BNTX

$101.95

1.78%

INSM

$143.57

4.21%

ONC

$292.94

2.03%

Cellectis Adr (CLLS)

Cellectis Adr Stock (CLLS) Company Profile

Compare CLLS vs VRTX, REGN, ARGX, ALNY, ONC

Cellectis Adr Stock (CLLS) Upgrades & Downgrades

Cellectis Adr (CLLS) 最新ニュース

European ADRs Slipped As Biopharma Dragged The Pack - Finimize

European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize

European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize

Jefferies assumes coverage on Cellectis stock with Buy rating - Investing.com

European ADRs Started The Week Higher In US Trading - Finimize

ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView — Track All Markets

Clear Street initiates Cellectis stock with Buy rating on CAR-T potential - Investing.com

Working capital per share of Cellectis S.A. Sponsored ADR – NASDAQ:CLLS - TradingView — Track All Markets

European ADRs Inch Up As 3D Printer Materialise Leads Gains - Finimize

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Sahm

Arbitration ruling partially terminates Cellectis-Servier license agreement - Investing.com

European ADRs Stay Put As Novo Nordisk Slides - Finimize

12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm

Moligo and Cellectis show promise in non-viral gene editing method - Investing.com India

Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications - Sahm

Cellectis reports breakthrough in non-viral gene editing technique - Investing.com

Citizens maintains Cellectis stock rating with $8 target ahead of ASH update - Investing.com

European ADRs Slip As Gains And Losses Balance Out - Finimize

Cellectis to Present a Development Update for eti-cel at ASH 2025 - Chartmill

European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail

Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines

Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com

Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga

Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView

Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews

Cellectis Adr (CLLS) 財務データ

収益

当期純利益

現金流量

EPS

CLLSに似た銘柄